AAPL328.22+3.26 (+1.00%) ▲|ABBV260.89-0.83 (-0.32%) ▼|ABT108.63-1.85 (-1.67%) ▼|ACN194.49+6.81 (+3.63%) ▲|ADBE284.31+4.52 (+1.61%) ▲|AMAT435.58-2.88 (-0.66%) ▼|AMD457.58+0.52 (+0.11%) ▲|AMGN444.03+1.19 (+0.27%) ▲|AMT177.67+4.75 (+2.75%) ▲|AMZN258.45+3.47 (+1.36%) ▲|AVGO354.44-12.80 (-3.49%) ▼|AXP330.27+0.29 (+0.09%) ▲|BA208.90+0.03 (+0.01%) ▲|BAC63.04+0.44 (+0.69%) ▲|BKNG196.53-3.07 (-1.54%) ▼|BLK1,115.05+7.97 (+0.72%) ▲|BMY67.86+0.20 (+0.29%) ▲|BNY163.70+1.66 (+1.02%) ▲|BRK-B507.73+2.49 (+0.49%) ▲|C137.87+3.53 (+2.62%) ▲|CAT796.71+4.43 (+0.56%) ▲|CL90.29+0.19 (+0.21%) ▲|CMCSA26.62-0.19 (-0.70%) ▼|COF219.85+3.25 (+1.50%) ▲|COP136.18-1.02 (-0.74%) ▼|COST928.93+0.45 (+0.05%) ▲|CRM264.64+7.71 (+3.00%) ▲|CSCO109.03-0.43 (-0.39%) ▼|CVS97.77+0.54 (+0.56%) ▲|CVX212.65+0.87 (+0.41%) ▲|DE693.95-4.42 (-0.63%) ▼|DHR208.54-1.37 (-0.65%) ▼|DIS107.62-0.36 (-0.33%) ▼|DUK121.66+1.10 (+0.91%) ▲|EMR149.81+0.83 (+0.55%) ▲|FDX320.65+4.11 (+1.30%) ▲|GD364.06-0.01 (0.00%) ▼|GE332.16+2.66 (+0.81%) ▲|GEV942.92+20.98 (+2.28%) ▲|GILD149.98+0.37 (+0.25%) ▲|GM86.82+1.95 (+2.30%) ▲|GOOG338.90+5.12 (+1.53%) ▲|GOOGL342.31+5.19 (+1.54%) ▲|GS1,034.79+30.37 (+3.02%) ▲|HD318.96+2.78 (+0.88%) ▲|HON207.92+1.85 (+0.90%) ▲|IBM233.68+1.98 (+0.85%) ▲|INTC91.24+1.19 (+1.32%) ▲|INTU347.75+4.81 (+1.40%) ▲|ISRG370.25-1.64 (-0.44%) ▼|JNJ278.23+3.02 (+1.10%) ▲|JPM361.28+5.06 (+1.42%) ▲|KO88.96+0.72 (+0.82%) ▲|LIN483.22-2.63 (-0.54%) ▼|LLY1,159.84-0.25 (-0.02%) ▼|LMT531.82+0.27 (+0.05%) ▲|LOW202.50+2.66 (+1.33%) ▲|LRCX287.79-0.53 (-0.18%) ▼|MA584.13-4.01 (-0.68%) ▼|MCD259.17-1.78 (-0.68%) ▼|MDLZ61.29-1.16 (-1.86%) ▼|MDT92.77+0.59 (+0.63%) ▲|META612.97+20.12 (+3.39%) ▲|MMM167.92-0.83 (-0.49%) ▼|MO69.87+0.31 (+0.44%) ▲|MRK151.70+0.06 (+0.04%) ▲|MS216.37+4.55 (+2.15%) ▲|MSFT510.21+13.39 (+2.70%) ▲|MU940.98-15.11 (-1.58%) ▼|NEE83.99+0.89 (+1.07%) ▲|NFLX82.32-0.41 (-0.50%) ▼|NKE38.58+0.34 (+0.88%) ▲|NOW143.96+7.24 (+5.30%) ▲|NVDA227.10+2.69 (+1.20%) ▲|ORCL154.63+8.88 (+6.09%) ▲|PEP139.76-0.77 (-0.54%) ▼|PFE28.81-0.21 (-0.72%) ▼|PG147.69+0.05 (+0.03%) ▲|PLTR182.95+13.49 (+7.96%) ▲|PM187.63-0.32 (-0.17%) ▼|QCOM169.26+0.22 (+0.13%) ▲|RTX201.61+0.83 (+0.41%) ▲|SBUX106.14-0.58 (-0.54%) ▼|SCHW110.13+1.89 (+1.75%) ▲|SO89.14+0.83 (+0.94%) ▲|SPG211.31+1.11 (+0.53%) ▲|T26.18+0.23 (+0.87%) ▲|TMO609.78+1.24 (+0.20%) ▲|TMUS188.89+1.59 (+0.85%) ▲|TSLA382.04+25.03 (+7.01%) ▲|TXN253.66-1.14 (-0.45%) ▼|UBER75.81-0.64 (-0.84%) ▼|UNH403.99+4.33 (+1.08%) ▲|UNP291.37+1.64 (+0.57%) ▲|UPS103.30+0.29 (+0.28%) ▲|USB63.55+0.78 (+1.23%) ▲|V377.27-1.14 (-0.30%) ▼|VZ50.74+0.52 (+1.03%) ▲|WFC89.24-0.03 (-0.03%) ▼|WMT109.09+3.00 (+2.83%) ▲|XOM163.58-0.58 (-0.35%) ▼|AAPL328.22+3.26 (+1.00%) ▲|ABBV260.89-0.83 (-0.32%) ▼|ABT108.63-1.85 (-1.67%) ▼|ACN194.49+6.81 (+3.63%) ▲|ADBE284.31+4.52 (+1.61%) ▲|AMAT435.58-2.88 (-0.66%) ▼|AMD457.58+0.52 (+0.11%) ▲|AMGN444.03+1.19 (+0.27%) ▲|AMT177.67+4.75 (+2.75%) ▲|AMZN258.45+3.47 (+1.36%) ▲|AVGO354.44-12.80 (-3.49%) ▼|AXP330.27+0.29 (+0.09%) ▲|BA208.90+0.03 (+0.01%) ▲|BAC63.04+0.44 (+0.69%) ▲|BKNG196.53-3.07 (-1.54%) ▼|BLK1,115.05+7.97 (+0.72%) ▲|BMY67.86+0.20 (+0.29%) ▲|BNY163.70+1.66 (+1.02%) ▲|BRK-B507.73+2.49 (+0.49%) ▲|C137.87+3.53 (+2.62%) ▲|CAT796.71+4.43 (+0.56%) ▲|CL90.29+0.19 (+0.21%) ▲|CMCSA26.62-0.19 (-0.70%) ▼|COF219.85+3.25 (+1.50%) ▲|COP136.18-1.02 (-0.74%) ▼|COST928.93+0.45 (+0.05%) ▲|CRM264.64+7.71 (+3.00%) ▲|CSCO109.03-0.43 (-0.39%) ▼|CVS97.77+0.54 (+0.56%) ▲|CVX212.65+0.87 (+0.41%) ▲|DE693.95-4.42 (-0.63%) ▼|DHR208.54-1.37 (-0.65%) ▼|DIS107.62-0.36 (-0.33%) ▼|DUK121.66+1.10 (+0.91%) ▲|EMR149.81+0.83 (+0.55%) ▲|FDX320.65+4.11 (+1.30%) ▲|GD364.06-0.01 (0.00%) ▼|GE332.16+2.66 (+0.81%) ▲|GEV942.92+20.98 (+2.28%) ▲|GILD149.98+0.37 (+0.25%) ▲|GM86.82+1.95 (+2.30%) ▲|GOOG338.90+5.12 (+1.53%) ▲|GOOGL342.31+5.19 (+1.54%) ▲|GS1,034.79+30.37 (+3.02%) ▲|HD318.96+2.78 (+0.88%) ▲|HON207.92+1.85 (+0.90%) ▲|IBM233.68+1.98 (+0.85%) ▲|INTC91.24+1.19 (+1.32%) ▲|INTU347.75+4.81 (+1.40%) ▲|ISRG370.25-1.64 (-0.44%) ▼|JNJ278.23+3.02 (+1.10%) ▲|JPM361.28+5.06 (+1.42%) ▲|KO88.96+0.72 (+0.82%) ▲|LIN483.22-2.63 (-0.54%) ▼|LLY1,159.84-0.25 (-0.02%) ▼|LMT531.82+0.27 (+0.05%) ▲|LOW202.50+2.66 (+1.33%) ▲|LRCX287.79-0.53 (-0.18%) ▼|MA584.13-4.01 (-0.68%) ▼|MCD259.17-1.78 (-0.68%) ▼|MDLZ61.29-1.16 (-1.86%) ▼|MDT92.77+0.59 (+0.63%) ▲|META612.97+20.12 (+3.39%) ▲|MMM167.92-0.83 (-0.49%) ▼|MO69.87+0.31 (+0.44%) ▲|MRK151.70+0.06 (+0.04%) ▲|MS216.37+4.55 (+2.15%) ▲|MSFT510.21+13.39 (+2.70%) ▲|MU940.98-15.11 (-1.58%) ▼|NEE83.99+0.89 (+1.07%) ▲|NFLX82.32-0.41 (-0.50%) ▼|NKE38.58+0.34 (+0.88%) ▲|NOW143.96+7.24 (+5.30%) ▲|NVDA227.10+2.69 (+1.20%) ▲|ORCL154.63+8.88 (+6.09%) ▲|PEP139.76-0.77 (-0.54%) ▼|PFE28.81-0.21 (-0.72%) ▼|PG147.69+0.05 (+0.03%) ▲|PLTR182.95+13.49 (+7.96%) ▲|PM187.63-0.32 (-0.17%) ▼|QCOM169.26+0.22 (+0.13%) ▲|RTX201.61+0.83 (+0.41%) ▲|SBUX106.14-0.58 (-0.54%) ▼|SCHW110.13+1.89 (+1.75%) ▲|SO89.14+0.83 (+0.94%) ▲|SPG211.31+1.11 (+0.53%) ▲|T26.18+0.23 (+0.87%) ▲|TMO609.78+1.24 (+0.20%) ▲|TMUS188.89+1.59 (+0.85%) ▲|TSLA382.04+25.03 (+7.01%) ▲|TXN253.66-1.14 (-0.45%) ▼|UBER75.81-0.64 (-0.84%) ▼|UNH403.99+4.33 (+1.08%) ▲|UNP291.37+1.64 (+0.57%) ▲|UPS103.30+0.29 (+0.28%) ▲|USB63.55+0.78 (+1.23%) ▲|V377.27-1.14 (-0.30%) ▼|VZ50.74+0.52 (+1.03%) ▲|WFC89.24-0.03 (-0.03%) ▼|WMT109.09+3.00 (+2.83%) ▲|XOM163.58-0.58 (-0.35%) ▼|
25.1 C
New York
Thursday, September 3, 2026

Tag: trial

newssourceFORcompanyinformationcontent1releasesmarket

Creative Medical Technology Holdings Secures FDA Fast Track Designation for CELZ-201-DDT – Advancing Breakthrough Therapy for Chronic Lower Back Pain

PHOENIX, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ), a clinical-stage biotechnology company focused on regenerative and immune cellular therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its lead investigational therapy, CELZ-201-DDT, for the treatment of degenerative disc disease (DDD), a major cause of chronic lower back pain and disability.

MediPharm Labs Positioned for Unique Opportunities on Possible Rescheduling of Cannabis in the United States

MediPharm Labs holds unique US Food and Drug Administration (FDA) site registration in relation to the manufacturing and release of pharmaceutical cannabis products.  MediPharm...

Telitacicept Meets Primary Endpoint in Phase III Trial for Primary Sjögren’s Syndrome in China

YANTAI, China, Aug. 13, 2025 /PRNewswire/ -- On August 13th, Remegen (688331.SH/09995.HK) announced that its global first-in-class BLyS (BAFF)/APRIL dual-target fusion protein drug, Telitacicept, met...

Daewoong Therapeutics Microneedle Patch Achieves Best-in-Class Bioavailability, Proving the Strength of Its Drug-Delivery Platform

More than 80% relative bioavailability compared with injectable obesity therapy, well above the roughly 30% reported for existing microneedle patches and setting a new...

Greywolf Therapeutics begins dosing of the first treatment to target the antigenic source of autoimmunity

Greywolf starts first trial of GRWD0715, aiming for a functional cure for autoimmunity by targeting its antigenic source.

HopeAI Joins Mayo Clinic Platform to Transform the Future of Drug Development with AI

NEW YORK, Aug. 12, 2025 /PRNewswire/ -- HopeAI, an emerging leader in applying artificial intelligence (AI) to accelerate new drug development, has officially joined...

Tumor-Infiltrating Lymphocyte Therapy Market Gains Momentum with Expanding Oncology Applications | DelveInsight

Over the last ten years, cell-based immunotherapy has emerged as a promising approach for treating solid tumors. Several companies, including Iovance Biotherapeutics, Obsidian Therapeutics,...

Tumor-Infiltrating Lymphocyte Therapy Market Gains Momentum with Expanding Oncology Applications | DelveInsight

Over the last ten years, cell-based immunotherapy has emerged as a promising approach for treating solid tumors. Several companies, including Iovance Biotherapeutics, Obsidian Therapeutics,...

FurZapper Gains Attention in 2025 as Reusable Pet Hair Removal Solution for Laundry

Eco-friendly, chemical-free design appeals to pet owners seeking sustainable ways to manage fur in washing machines and dryers. 
Eco-friendly, chemical-free design appeals to pet owners seeking sustainable ways to manage fur in washing machines and dryers.

Leatt Corp Announces Share Repurchase Program

CAPE TOWN, South Africa, Aug. 12, 2025 /PRNewswire/ -- Leatt Corporation (OTCQB: LEAT), a leading developer and marketer of head-to-toe protective equipment for MOTO,...

Eupraxia Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

VICTORIA, British Columbia, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, today announced its financial results for the second quarter of 2025 and provided a business update. All dollar values are in U.S. dollars unless stated otherwise.

vTv Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

•   First study participant randomized in Phase 3 CATT1 trial evaluating cadisegliatin for the treatment of type 1 diabetes with data expected in second half of 2026

Armata Pharmaceuticals Announces Second Quarter 2025 Results and Provides Corporate Update

Entered into secured credit agreement with Innoviva for $15 million maturing in 2029 Announced positive topline results from the Phase 1b/2a diSArm trial for AP-SA02 LOS...

New Study Confirms LP815® Probiotic Reduces Canine Anxiety and Aggression

With behavioral issues affecting up to 85% of dogs, LP815 provides a clinically supported approach to ease anxiety, reduce aggression, and support more restful,...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsTrial

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers